Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058195 | 0.87 | TSHR (0.33) | — | |
| SCHEMBL13018008 | 0.85 | — | — | |
| SCHEMBL8175429 | 0.84 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL13447352 | 0.84 | — | — | |
| SCHEMBL13917872 | 0.84 | — | — | |
| SCHEMBL1975737 | 0.82 | — | — | |
| SCHEMBL10222591 | 0.82 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL19265365 | 0.82 | TSHR (0.30) | — | |
| SCHEMBL24747411 | 0.80 | CYP2D6 (0.32) | — | |
| SCHEMBL21726284 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054953-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2017152857-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR CONTAINING NITROGEN ALKYLATED AND ARYLATED SULPHOXIDE IMINES | 中国科学院上海有机化学研究所 | 2017-09-14 | — | — | WO | disclosed |
| EP-2066329-B1 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOBUTYLMETHYLAMINES | REVIVA PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2875021-B1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170000712-A1 | SUNLESS TANNING COMPOUNDS AND COMPOSITIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-01-05 | — | — | US | disclosed |
| US-9403778-B2 | Agents that prevent or repair skin damage | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-08-02 | — | — | US | disclosed |
| WO-2015003095-A1 | SUNLESS TANNING COMPOUNDS AND COMPOSITIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-01-08 | — | — | WO | disclosed |
| US-20140350036-A1 | AGENTS THAT PREVENT OR REPAIR SKIN DAMAGE | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2014-11-27 | — | — | US | disclosed |
| US-20120253034-A1 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE LINKED IMIDAZO[1,5-A]PYRIDINE CONJUGATES AS POTENTIAL ANTITUMOUR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-10-04 | — | — | US | disclosed |
| WO-2012003501-A2 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2010091268-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2008034142-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253034-A1 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE LINKED IMIDAZO[1,5-A]PYRIDINE CONJUGATES AS POTENTIAL ANTITUMOUR AGENTS AND PROCESS FOR THE PREPARATION THEREOF | GABRA3, GABRA5, GABRA1 | ALDH1A1 348/4885 |
| US-20170000712-A1 | SUNLESS TANNING COMPOUNDS AND COMPOSITIONS | TYR, SUN2, ERCC4 | ALDH1A1 1404/4885 |
| US-20140350036-A1 | AGENTS THAT PREVENT OR REPAIR SKIN DAMAGE | OGG1, ERCC4, ERCC1 | ALDH1A1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.